Anafranil
(Clomipramine)ApprovedSmall molecule
Clomipramine is a tricyclic antidepressant used to treat obsessive-compulsive disorder, a condition where people experience unwanted repetitive thoughts and feel compelled to perform certain behaviors repeatedly. The medication works by increasing serotonin levels in the brain, which helps restore mental balance.[2] Anafranil is currently approved and in use across 2 indications[4].[1]
Anafranil is one of 47 small molecule programs targeting Treatment Resistant Depression. It is currently in Approved.
2
Indications
9
Total Trials
0
Active Trials
46
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
32 competitors in Treatment Resistant Depression
#DrugCompanyPhaseTrials
1Ketalar
AAultman Health Foundation
Approved
Spravato
WWim Janssens
Approved
Risperdal
WWim Janssens
Approved
Bayer Aspirin
BayerApproved
Lithobid
SSolvay Pharmaceuticals
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Abilify
OtsukaApproved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Mirapex
Boehringer IngelheimApproved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Obsessive-Compulsive Disorder4 trials
Premature Ejaculation2 trials
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Dec 29, 1989
ANAFRANIL
NDA NDA019906
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Anafranil drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Clomipramine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]